Ducentis Overview
- Year Founded
-
2012

- Status
-
Acquired/Merged
- Employees
-
3

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$428M
- Investors
-
1
Ducentis General Information
Description
Developer of novel therapies designed to provide treatment for inflammation and autoimmune diseases. The company offers an axis that is distinct from conventional immunomodulators which exploit blockade mechanisms to inhibit the action of pro-inflammatory molecules which transmits a deactivating signal to activated immune cells and thus acts to promote tolerance and restore immune homeostasis.
Contact Information
Website
www.ducentisbio.comCorporate Office
- 264 Banbury Road
- Oxfordshire
- Oxford OX2 7DY
- England, United Kingdom
Corporate Office
- 264 Banbury Road
- Oxfordshire
- Oxford OX2 7DY
- England, United Kingdom
Ducentis Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Merger/Acquisition | 28-Dec-2022 | $428M | Completed | Pre-Clinical Trials | ||
6. Later Stage VC (Series A) | Cancelled | Pre-Clinical Trials | ||||
5. Later Stage VC | 12-Oct-2022 | Completed | Generating Revenue | |||
4. Later Stage VC | 14-Jun-2019 | Completed | Pre-Clinical Trials | |||
3. Later Stage VC | 03-Apr-2018 | Completed | Startup | |||
2. Early Stage VC | 17-Mar-2016 | $56.7K | $181K | Completed | Startup | |
1. Early Stage VC | 13-Jul-2015 | $125K | $125K | Completed | Startup |
Ducentis Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | ||||||||
Ordinary | ||||||||
A Ordinary | ||||||||
Ordinary | ||||||||
Ordinary | ||||||||
Ordinary | ||||||||
Ordinary | 222,223 | $0.000112 | $0.2 | $0.2 | 1x | $0.2 | 2.92% | |
Ordinary | 357,143 | $0.000112 | $0.16 | $0.16 | 1x | $0.16 | 4.7% |
Ducentis Comparisons
Industry
Financing
Details
Ducentis Competitors (2)
One of Ducentis’s 2 competitors is Pathios Therapeutics, a Venture Capital-Backed company based in Abingdon, United Kingdom.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Pathios Therapeutics | Venture Capital-Backed | Abingdon, United Kingdom | ||||
Eli Lilly | Corporation | Indianapolis, IN |
Ducentis Patents
Ducentis Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-202418600-D0 | Composition and method of using mutated cd200 fusion protein | Pending | 18-Dec-2024 | ||
GB-202320145-D0 | Composition and method of using mutated cd200 fusion protein | Inactive | 29-Dec-2023 | ||
GB-202306711-D0 | Novel proteins | Inactive | 05-May-2023 | ||
GB-202218501-D0 | Mutated cd200 proteins and methods of use therof | Pending | 08-Dec-2022 | ||
GB-2626300-A | Mutated cd200 proteins and methods of use therof | Pending | 08-Dec-2022 | C07K14/70596 |
Ducentis Signals
Ducentis Former Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
LifeArc Ventures | Venture Capital | Minority | ||
Oxford Technology Management | Venture Capital | Minority |
Ducentis FAQs
-
When was Ducentis founded?
Ducentis was founded in 2012.
-
Where is Ducentis headquartered?
Ducentis is headquartered in Oxford, United Kingdom.
-
What is the size of Ducentis?
Ducentis has 3 total employees.
-
What industry is Ducentis in?
Ducentis’s primary industry is Biotechnology.
-
Is Ducentis a private or public company?
Ducentis is a Private company.
-
What is the current valuation of Ducentis?
The current valuation of Ducentis is
. -
What is Ducentis’s current revenue?
The current revenue for Ducentis is
. -
How much funding has Ducentis raised over time?
Ducentis has raised $7.47M.
-
Who are Ducentis’s investors?
LifeArc Ventures and Oxford Technology Management have invested in Ducentis.
-
Who are Ducentis’s competitors?
Pathios Therapeutics and Eli Lilly are competitors of Ducentis.
-
When was Ducentis acquired?
Ducentis was acquired on 28-Dec-2022.
-
Who acquired Ducentis?
Ducentis was acquired by Arcutis Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »